Information in the literature related to the biological and/or pharmacological properties of molracetam is absent.

Eticlopride {2S(−)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide} is an antagonist at dopamine D2 and D3 receptors. It is widely used for in vivo, in vitro, and ex vivo examination of D2/D3 receptors densities and function. Eticlopride exerts antipsychotic activity in animals.

Etiproston is a synthetic analog of prostaglandin F2α. Etiproston induces luteal regression. Etiproston is used in veterinary.

Etisomicin is a semisynthetic aminoglycoside antibiotic.

Esafloxacin (7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid) is an antibacterial agent.

Roxoperone was developed as an anxiolytic agent. Information about the further development of this compound is not available.

Sabiporide was developed as a specific Na(+)/H(+) exchanger (NHE1) inhibitor. Sabiporide possessed a cardioprotective effect that was shown in a preclinical model of myocardial infarction in the rat. In addition, experiments on rodents have revealed that the administration of sabiporide improved cardiovascular function and attenuates organ injury from severe sepsis. However, the development of this drug appears to be discontinued.

Sagandipine was developed as a calcium channel blocker. Information about the current use of this compound is not available.

Xidecaflur is one of the particularly preferred amine hydrofluorides that was used to the oral care composition. Information about the current use of this agent is not available.

Salafibrate was developed as a hypocholesterolemic agent. Information about the further study of this compound is not available.